STOCK TITAN

Savara (SVRA) Stock News, Mar-May 2025

SVRA NASDAQ

Savara Inc. develops therapies for rare respiratory diseases, with a lead program in molgramostim inhalation solution, conditionally named MOLBREEVI, for autoimmune pulmonary alveolar proteinosis. Molgramostim is a recombinant human GM-CSF delivered through an investigational eFlow Nebulizer System developed for inhalation of the large-molecule therapy.

Recurring company developments include clinical data from the IMPALA-2 program, regulatory submissions and agency-review updates in the U.S., Europe and the U.K., financial results, financing arrangements, equity inducement grants and investor conference participation. Savara's updates also note that MOLBREEVI is not approved in any indication.

Rhea-AI Summary
Savara (SVRA) has granted inducement awards to five new employees as part of their employment compensation package. The awards include: • Stock options to purchase 85,000 shares with an exercise price of $2.91 per share • Restricted stock units (RSUs) covering 75,000 shares The options have a 10-year term and vest quarterly (1/16th each quarter), while the RSUs vest fully after two years. These equity awards were granted under Savara's 2021 Inducement Equity Incentive Plan, complying with NASDAQ Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.69%
Tags
none
-
Rhea-AI Summary

Savara Inc. (SVRA), a clinical stage biopharmaceutical company specializing in rare respiratory diseases, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's management team will conduct one-on-one meetings and deliver a presentation on June 4, 2025, at 9:20 AM ET. Investors can access the live webcast and replay of the presentation through the "Events & Presentations" section of Savara's corporate website, where it will remain available for 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
none
-
Rhea-AI Summary
Savara (SVRA) presented new data from its Phase 3 IMPALA-2 trial of molgramostim for autoimmune Pulmonary Alveolar Proteinosis (aPAP) at ATS 2025. The results showed that molgramostim significantly reduced surfactant burden with a mean reduction in GGO score of -2.1 vs. -1.1 for placebo (P=0.0004). Only 7.4% of molgramostim patients required rescue whole lung lavages compared to 13.3% in the placebo group. The drug also demonstrated significant improvements in health-related quality of life measures, including better SGRQ Impact scores (P=0.0084), reduced severity of breathing problems at Week 24 (P=0.0305) and Week 48 (P=0.0049), and improved daily physical activity levels at Week 24 (P=0.0368) and Week 48 (P=0.0193).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.95%
Tags
Rhea-AI Summary

Savara Inc. (SVRA) has reported its Q1 2025 financial results and provided significant business updates. The company completed the submission of a Biologics License Application (BLA) to the FDA for MOLBREEVI, targeting autoimmune PAP treatment, with a request for priority review. A potential PDUFA date is expected by year-end, with a U.S. launch planned for early 2026.

The company secured a non-dilutive debt financing of up to $200M in March, including $30M at close for refinancing existing debt. With ~$172.5M in cash and short-term investments as of March 31, 2025, Savara believes it is capitalized into 2H 2027. Q1 2025 resulted in a net loss of $26.6M ($0.12 per share), compared to $20.3M in Q1 2024. R&D expenses increased by 14% to $19.2M, while G&A expenses rose 64.1% to $9.2M.

The company plans to submit Marketing Authorization Applications for MOLBREEVI to both European and UK regulatory agencies by year-end.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.67%
Tags
-
Rhea-AI Summary

Savara Inc. (SVRA), a clinical stage biopharmaceutical company specializing in rare respiratory diseases, has announced its participation in the upcoming H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference. The company's management team will conduct one-on-one meetings and deliver a presentation on May 20, 2025, at 4:30 PM ET/1:30 PM PT. Investors and interested parties can access the live webcast and replay through the "Events & Presentations" section of Savara's corporate website, with the recording remaining available for 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.66%
Tags
none
-
Rhea-AI Summary

Savara Inc. (SVRA), a clinical stage biopharmaceutical company specializing in rare respiratory diseases, has announced its upcoming participation in the Citizens Life Sciences Conference. The company's management team will conduct one-on-one meetings and participate in a fireside chat on Thursday, May 8, 2025 at 10:30am EST/7:30am PST. The event will be accessible via live webcast and will remain available for replay on Savara's corporate website for 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.29%
Tags
none
Rhea-AI Summary

Savara Inc. (Nasdaq: SVRA) has granted inducement awards to seven new employees as of April 9, 2025. The awards include stock options for 107,000 shares and restricted stock units (RSUs) covering 83,000 shares, granted under the company's 2021 Inducement Equity Incentive Plan.

The stock options have an exercise price of $2.74 per share, matching the closing price on NASDAQ Global Market on the grant date. These options have a 10-year term and vest quarterly at 1/16th of the shares. The RSUs will fully vest after two years, contingent on continued employment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
none
-
Rhea-AI Summary

Savara Inc. (Nasdaq: SVRA) has announced upcoming encore presentations of top-line data from their pivotal Phase 3 IMPALA-2 clinical trial of molgramostim inhalation solution for treating autoimmune Pulmonary Alveolar Proteinosis (aPAP). The presentations will be featured at two major scientific conferences:

1. The 65th Congress of the German Society of Pneumology (DGP) in Leipzig, Germany (April 9-12, 2025), where Dr. Francesco Bonella will present findings showing molgramostim's improvements in pulmonary gas exchange, quality of life, and exercise capacity in aPAP patients.

2. The 65th Annual Meeting of the Japanese Respiratory Society (JRS) in Tokyo, Japan (April 11-13, 2025), where Dr. Yoshikazu Inoue will present the IMPALA-2 Phase 3 trial results.

The presentations will subsequently be made available on Savara's corporate website under the Congresses & Publications section.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.45%
Tags
conferences clinical trial
-
Rhea-AI Summary

Savara Inc. (SVRA) has completed the submission of its Biologics License Application (BLA) to the FDA for MOLBREEVI, a potential first-ever treatment for autoimmune Pulmonary Alveolar Proteinosis (aPAP). The company has requested Priority Review and expects a possible PDUFA date by year-end, targeting early 2026 for commercial launch.

Financial highlights for Q4 2024 include a net loss of $29.0 million ($0.13 per share), with R&D expenses of $23.3 million and G&A expenses of $7.8 million. For full-year 2024, net loss was $95.9 million ($0.48 per share), with R&D expenses increasing 76.3% to $78.0 million and G&A expenses rising 59.8% to $25.0 million.

The company maintains a strong financial position with $196.3 million in cash and short-term investments as of December 31, 2024, providing runway through Q2 2027, excluding an additional debt financing of up to $200 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
Rhea-AI Summary

Savara Inc. (SVRA) has secured a non-dilutive debt financing agreement with Hercules Capital for up to $200 million. The initial $30 million will refinance existing debt, with an additional $100 million available upon FDA approval of MOLBREEVI and certain milestones. The remaining $70 million can be accessed at Hercules' discretion.

The five-year loan agreement features a 36-month interest-only period, extendable to 60 months upon FDA approval of MOLBREEVI. This financing follows Savara's Biologics License Application submission to the FDA for MOLBREEVI, a potential first-in-class therapy for autoimmune pulmonary alveolar proteinosis (aPAP). With Priority Review, approval could come by year-end, coinciding with planned European Marketing Authorization Application submission.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
none

FAQ

What is the current stock price of Savara (SVRA)?

Savara (SVRA) last closed at $4.64.

What is the market cap of Savara (SVRA)?

The market cap of Savara (SVRA) is approximately $1.0B.